For many people with leukemia, lymphoma, bone marrow failure, or another serious blood disorder, a donor stem cell transplant can offer something enormously valuable: a new blood-forming and immune system. Unfortunately, the new immune system does not always arrive with a complete instruction manual.
Sometimes, immune cells from the donor identify the recipient’s healthy tissues as foreign and begin attacking them. This complication is called graft-versus-host disease, commonly shortened to GVHD.
GVHD can be mild and manageable, or it can become severe and life-threatening. It may affect one organ or several, appear shortly after a transplant, or develop months or even years later. The encouraging news is that transplant teams have become much better at preventing, recognizing, and treating the condition. The less encouraging news is that GVHD can be unpredictablerather like a smoke alarm that occasionally detects toast but must still be taken seriously.
What Does Graft-Versus-Host Disease Mean?
The name sounds complicated, but its three parts explain the problem:
- Graft: The donated blood-forming stem cells and the immune cells they produce.
- Host: The person who receives the transplant.
- Disease: The inflammatory damage that occurs when donor immune cells attack the host’s tissues.
GVHD most commonly occurs after an allogeneic hematopoietic stem cell transplant, meaning the stem cells come from another person. These cells may be collected from bone marrow, circulating blood, or umbilical cord blood. GVHD is not generally associated with an autologous transplant, in which a patient receives their own previously collected cells, although unusual GVHD-like syndromes have been reported.
Rare forms of graft-versus-host disease can also occur after certain blood transfusions or solid-organ transplants. However, most patient discussions about GVHD concern donor blood or marrow transplantation.
Why Does GVHD Happen?
Donor immune cells are supposed to rebuild the recipient’s immune defenses. They may also attack remaining cancer cells, producing a beneficial response called the graft-versus-leukemia or graft-versus-tumor effect.
The trouble begins when donor T cells detect differences between the recipient’s cells and the donor’s cells. Even when a donor and recipient are carefully matched, small biological differences remain. Activated donor cells may interpret those differences as a threat and launch an inflammatory response against healthy tissue.
In plain English, the donor immune system is trying to protect its new home but has not yet learned which furniture belongs there.
The likelihood and severity of GVHD are influenced by several factors, including:
- How closely the donor and recipient’s human leukocyte antigens, or HLA markers, match
- The donor relationship and type of donor used
- The source of the donated stem cells
- The ages and health characteristics of the donor and recipient
- The conditioning treatment given before transplantation
- The medications and techniques used to prevent GVHD
- A previous episode of acute GVHD, which can raise the risk of chronic disease
A less-than-perfect HLA match does not automatically mean severe GVHD will occur. Modern preventive approaches have made transplants possible for many people who do not have a fully matched sibling or unrelated donor.
Acute Versus Chronic GVHD
Graft-versus-host disease is traditionally divided into acute GVHD and chronic GVHD. Older explanations often say that acute GVHD occurs during the first 100 days after transplant and chronic GVHD starts afterward. Timing still provides useful context, but it is no longer the whole definition.
Doctors now classify GVHD primarily according to its clinical features. Acute symptoms can appear after day 100, a pattern called late acute GVHD. A person can also develop characteristics of acute and chronic disease at the same time, known as overlap GVHD. Day 100, in other words, is not a magical immune-system curfew.
Acute GVHD
Acute graft-versus-host disease usually develops during the early post-transplant period and primarily targets the skin, gastrointestinal tract, and liver.
Common signs include:
- A red, itchy, tender, or burning skin rash
- Nausea, vomiting, or loss of appetite
- Frequent, watery, or sometimes bloody diarrhea
- Abdominal pain or cramping
- Yellowing of the skin or eyes
- Dark urine or abnormal liver-test results
Acute GVHD is graded according to the organs involved and the severity of the damage. Mild disease may affect a limited area of skin, while severe disease can cause extensive skin injury, major intestinal fluid loss, liver dysfunction, infection, dehydration, and other dangerous complications.
Chronic GVHD
Chronic graft-versus-host disease often develops several months after transplantation, but it can appear earlier or much later. It may resemble an autoimmune or connective-tissue disorder and can affect nearly any part of the body.
Possible chronic GVHD symptoms include:
- Skin: Dryness, itching, rashes, color changes, thickening, tightening, sores, or reduced flexibility
- Eyes: Dryness, grittiness, burning, redness, light sensitivity, or blurry vision
- Mouth: Dry mouth, ulcers, pain, sensitivity to spicy foods, white patches, or taste changes
- Lungs: Persistent dry cough, wheezing, shortness of breath, or reduced exercise tolerance
- Joints and fascia: Stiffness, cramps, limited range of motion, or difficulty fully extending a limb
- Digestive tract: Trouble swallowing, nausea, diarrhea, poor appetite, or unintended weight loss
- Liver: Abnormal blood tests, itching, dark urine, or jaundice
- Genital tissues: Dryness, irritation, narrowing, sores, pain, or sexual difficulties
- Hair and nails: Hair thinning, brittle nails, ridges, or nail loss
Some symptoms are easy to overlook. A person may assume that dry eyes come from screen time, that stiffness comes from sleeping badly, or that a cough is simply taking forever to leave. After an allogeneic transplant, however, persistent or changing symptoms deserve a call to the transplant team.
How Is GVHD Diagnosed?
There is no single at-home test that confirms GVHD. Diagnosis begins with the patient’s symptoms, medical history, transplant timeline, physical examination, and laboratory results.
Depending on the affected area, the evaluation may include:
- Blood tests to evaluate liver function and blood-cell counts
- A skin, liver, or gastrointestinal biopsy
- Stool tests to look for infection
- Pulmonary function tests and chest imaging
- Eye examinations and tear-production testing
- Oral, dental, gynecologic, or urologic evaluation
- Measurements of joint movement, strength, and functional ability
Infections, medication reactions, chemotherapy effects, nutritional problems, and other transplant complications can imitate GVHD. Doctors therefore try to confirm the cause rather than blaming every post-transplant sneeze on the graft.
Acute disease is commonly assigned a grade based on organ involvement. Chronic GVHD is generally described as mild, moderate, or severe based on the number of organs affected and how seriously their function is impaired.
How Is Graft-Versus-Host Disease Treated?
Treatment aims to calm the donor immune response, relieve symptoms, preserve organ function, and avoid excessive suppression of the immune system. That last goal matters because stronger immunosuppression can increase vulnerability to bacterial, viral, and fungal infections.
Localized Treatment
Mild GVHD affecting a limited area may be managed with therapies applied directly to the affected tissue. Examples include corticosteroid skin creams, medicated mouth rinses, lubricating or prescription eye drops, topical genital treatments, or inhaled medications for certain lung problems.
Supportive therapies are not decorative extras. Physical therapy can help prevent contractures and loss of movement. Occupational therapy can make daily activities easier. Nutritional support, specialized dental care, eye care, wound management, and pelvic floor therapy may substantially improve comfort and function.
Systemic Treatment
When GVHD is widespread, progressing, or threatening an organ, systemic corticosteroids such as prednisone are commonly used as initial therapy. Steroids reduce inflammation quickly, but prolonged treatment can cause muscle weakness, bone loss, mood changes, elevated blood sugar, weight changes, cataracts, and infection risk.
If acute GVHD does not respond adequately to steroids, it is called steroid-refractory acute GVHD. Ruxolitinib is an FDA-approved option for certain adults and children age 12 or older with steroid-refractory acute disease. A mesenchymal stromal cell product, remestemcel-L-rknd, is another approved treatment for certain pediatric patients with steroid-refractory acute GVHD.
For chronic GVHD that continues despite initial systemic therapy, available options may include ruxolitinib, ibrutinib, belumosudil, or axatilimab. Eligibility depends on factors such as age, weight, prior treatments, organ involvement, blood counts, infection risk, and other medical conditions.
Extracorporeal photopheresis may also be used. During this procedure, some of the patient’s white blood cells are collected, treated with a light-activated medicine, exposed to ultraviolet light, and returned to the bloodstream. It sounds suspiciously like science fiction, but it has an established role in selected cases of chronic GVHD.
No medication is ideal for every patient. A transplant specialist may combine systemic and localized treatments, adjust doses gradually, or recommend a clinical trial when standard therapies are not producing enough improvement.
Can GVHD Be Prevented?
Transplant centers use several strategies to lower the risk of GVHD. The plan is selected according to the donor, stem-cell source, recipient, diagnosis, and transplant protocol.
Preventive measures may include:
- Choosing the best available HLA-matched donor
- Giving medications such as tacrolimus, cyclosporine, methotrexate, or mycophenolate
- Using post-transplant cyclophosphamide to control harmful donor immune cells
- Adding abatacept in appropriate transplant settings
- Removing or modifying selected T-cell populations from the graft
- Using a bone marrow or cord blood graft when clinically appropriate
Patients also play an important role. Taking preventive medication exactly as directed, protecting the skin from excessive sun exposure, attending follow-up appointments, and reporting new symptoms promptly can reduce complications and support earlier treatment.
Medication should never be stopped or reduced without guidance from the transplant team, even when a patient feels well. GVHD can appear or flare as immunosuppressive therapy is tapered.
When Should You Contact the Transplant Team?
After a donor transplant, patients should report new, persistent, or worsening symptoms rather than waiting for the next routine appointment. Contact the transplant team promptly for:
- A new rash, blistering, skin pain, or rapid skin changes
- Repeated vomiting or an inability to keep medicine down
- New diarrhea, especially frequent, watery, or bloody stools
- Yellow skin or eyes, dark urine, or pale stools
- Shortness of breath, wheezing, or a persistent cough
- Severe dry eyes, eye pain, light sensitivity, or vision changes
- Mouth sores that interfere with eating or drinking
- New tightness, weakness, stiffness, or loss of joint movement
- Genital pain, sores, dryness, or narrowing
- Fever or any sign of infection
Patients should follow their center’s emergency instructions because recommendations can differ. Severe breathing difficulty, confusion, heavy bleeding, extreme weakness, or signs of serious dehydration require urgent medical evaluation.
What Living With GVHD Can Feel Like
The following examples are composite illustrations based on commonly reported patient experiences. They do not describe specific individuals and are not substitutes for medical advice.
The Early-Transplant Experience
Imagine that someone is three weeks past an allogeneic stem cell transplant. Every day already involves temperature checks, medication schedules, blood tests, food-safety rules, and a sincere wish never to see another hospital wristband.
Then a red rash appears across the upper chest. A few hours later, diarrhea begins. The patient may wonder whether the symptoms came from a medication, hospital food, an infection, or GVHD. That uncertainty can be frightening, particularly because patients are repeatedly told to watch for complications without being expected to diagnose them.
The useful response is not to solve the mystery alone. It is to call the transplant team, describe the symptoms, count the bowel movements, photograph the rash if instructed, and explain when everything began. Those details help clinicians decide whether testing, medication changes, hydration, or hospital evaluation is needed.
When treatment begins quickly and the symptoms improve, relief can be mixed with frustration. Prednisone may control inflammation but disrupt sleep, increase appetite, alter mood, and make muscles feel weaker. A patient can be grateful that the medicine works while also being thoroughly unimpressed by its personality.
The Chronic, Less-Visible Experience
Another person may feel relatively well six months after transplant but gradually develop dry eyes, mouth sensitivity, and stiffness in the wrists. None of the symptoms seems dramatic by itself. Together, however, they can reshape an ordinary day.
Reading becomes uncomfortable because the eyes burn. Toast feels like sandpaper because the mouth is dry. Opening a jar becomes difficult because the connective tissue around the wrists has tightened. Friends may say, “You look great,” which is kindly meant but can feel strange when nearly every activity requires adjustment.
Chronic GVHD often involves this invisible workload. Patients schedule visits with transplant specialists, dermatologists, ophthalmologists, dentists, pulmonologists, rehabilitation therapists, and other clinicians. They may use several topical treatments while taking systemic medication and infection-prevention drugs. Managing the condition can resemble a part-time administrative job, except the paperwork occasionally asks about stool consistency.
A practical symptom log can reduce some of that burden. Useful notes may include photographs of skin changes, daily temperature, bowel patterns, eye-drop use, weight, breathing symptoms, range-of-motion changes, and the time each medication was taken. The goal is not to become obsessed with every sensation. It is to notice meaningful trends and communicate them clearly.
The Caregiver Experience
Caregivers often become medication organizers, transportation coordinators, meal planners, note-takers, and emotional shock absorbers. They may watch for signs of GVHD while trying not to make the patient feel as though they are under permanent surveillance.
One helpful approach is to divide responsibilities explicitly. The patient might track symptoms and perform prescribed exercises, while the caregiver manages the medication list and appointment calendar. Written questions can be prepared before clinic visits so that fatigue or anxiety does not erase them from memory.
Caregivers also need breaks, sleep, medical attention, and emotional support of their own. Exhaustion does not prove devotion. It proves that humans require maintenance, which is medically inconvenient but biologically nonnegotiable.
Finding a New Version of Normal
Recovery from GVHD is rarely a perfectly straight line. Symptoms may improve, flare during medication tapering, or shift from one organ system to another. Progress may mean walking farther, eating without mouth pain, using fewer eye drops, sleeping through the night, or returning to work with accommodations.
Many patients benefit from setting small functional goals rather than waiting for one grand “back to normal” moment. Physical rehabilitation, careful sun protection, adequate nutrition, vaccination planning, infection prevention, mental health care, and peer support can all contribute to recovery.
Most importantly, a diagnosis of GVHD does not automatically mean that the transplant has failed. The condition reflects donor immune activity, and many cases can be controlled. Treatment may require persistence and a multidisciplinary team, but new therapies have expanded the available options considerably.
Conclusion
Graft-versus-host disease is an immune complication most often seen after an allogeneic stem cell or bone marrow transplant. It develops when immune cells created from the donor graft attack the recipient’s healthy tissues.
Acute GVHD commonly affects the skin, gastrointestinal tract, and liver. Chronic GVHD can involve those areas as well as the eyes, mouth, lungs, joints, fascia, genital tissues, hair, and nails. Because its symptoms can resemble infections, medication side effects, and other transplant complications, evaluation by an experienced transplant team is essential.
Preventive medications have lowered the risk of GVHD, while corticosteroids, targeted drugs, localized therapies, photopheresis, rehabilitation, and supportive care provide multiple ways to manage it. Early reporting remains one of the most valuable tools patients and caregivers have. After a donor transplant, a new symptom is not something to hide until the next appointmentit is information the medical team can use.
Note: This article is intended for general education and does not replace individualized care from a transplant specialist. Its medical content was synthesized from guidance and patient resources published by the National Cancer Institute, National Institutes of Health, National Marrow Donor Program, U.S. Food and Drug Administration, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, Johns Hopkins Medicine, Dana-Farber Cancer Institute, MD Anderson Cancer Center, Yale Medicine, the American Cancer Society, ASTCT, BMT InfoNet, and other U.S. transplant authorities.
